124 related articles for article (PubMed ID: 38205842)
1. Do survivors of borderline ovarian tumors have susceptibility to secondary primary malignancies? A SEER population-based study.
Wang J; Du Y; Kang Y
Int J Gynaecol Obstet; 2024 Jun; 165(3):1229-1236. PubMed ID: 38205842
[TBL] [Abstract][Full Text] [Related]
2. Trends in the risk and burden of second primary malignancy among survivors of smoking-related cancers in the United States.
Adjei Boakye E; Buchanan P; Hinyard L; Osazuwa-Peters N; Simpson MC; Schootman M; Piccirillo JF
Int J Cancer; 2019 Jul; 145(1):143-153. PubMed ID: 30613963
[TBL] [Abstract][Full Text] [Related]
3. Increased incidence of second primary malignancy in patients with malignant astrocytoma: a population-based study.
Wang W
Biosci Rep; 2019 Jun; 39(6):. PubMed ID: 31138756
[TBL] [Abstract][Full Text] [Related]
4. Risk of Second Primary Tumors After Childhood and Adolescent Ovarian Malignancies: A SEER Analysis (1973-2011).
Nasioudis D; Ramer I; Sisti G; Fambrini M
J Pediatr Adolesc Gynecol; 2015 Dec; 28(6):522-5. PubMed ID: 26152647
[TBL] [Abstract][Full Text] [Related]
5. The risk and prognosis of secondary primary malignancy in lung cancer: a population-based study.
Hong J; Wei R; Nie C; Leonteva A; Han X; Du X; Wang J; Zhu L; Tian W; Zhou H
Future Oncol; 2021 Nov; 17(33):4497-4509. PubMed ID: 34402680
[TBL] [Abstract][Full Text] [Related]
6. Second Primary Malignant Neoplasms and Survival in Adolescent and Young Adult Cancer Survivors.
Keegan THM; Bleyer A; Rosenberg AS; Li Q; Goldfarb M
JAMA Oncol; 2017 Nov; 3(11):1554-1557. PubMed ID: 28426850
[TBL] [Abstract][Full Text] [Related]
7. Mucinous borderline ovarian tumor versus invasive well-differentiated mucinous ovarian cancer: Difference in characteristics and outcomes.
Matsuo K; Machida H; Mandelbaum RS; Grubbs BH; Roman LD; Sood AK; Gershenson DM
Gynecol Oncol; 2019 May; 153(2):230-237. PubMed ID: 30797590
[TBL] [Abstract][Full Text] [Related]
8. Risk of specific types of ovarian cancer after borderline ovarian tumors in Denmark: A nationwide study.
Hannibal CG; Frederiksen K; Vang R; Kurman RJ; Kjaer SK
Int J Cancer; 2020 Aug; 147(4):990-995. PubMed ID: 31930502
[TBL] [Abstract][Full Text] [Related]
9. Risk of secondary malignancies in ovarian cancer survivors: 52,680 patients analyzed with over 40 years of follow-up.
Casper AC; Parsons MW; Chipman J; Burt LM; Suneja G; Maurer KA; Gaffney DK
Gynecol Oncol; 2021 Aug; 162(2):454-460. PubMed ID: 34092413
[TBL] [Abstract][Full Text] [Related]
10. Risk and subtypes of secondary primary malignancies in diffuse large B-cell lymphoma survivors change over time based on stage at diagnosis.
Major A; Smith DE; Ghosh D; Rabinovitch R; Kamdar M
Cancer; 2020 Jan; 126(1):189-201. PubMed ID: 31509235
[TBL] [Abstract][Full Text] [Related]
11. Second primary malignancies after ovarian cancer: A SEER-based analysis (1975-2016).
Yang Z; Liu X; Yang X; Liao QP
Taiwan J Obstet Gynecol; 2022 Jan; 61(1):80-85. PubMed ID: 35181052
[TBL] [Abstract][Full Text] [Related]
12. Malignancies diagnosed before and after anal squamous cell carcinomas: A SEER registry analysis.
Jani KS; Lu SE; Murphy JD; Romesser PB; Jethwa KR; Li D; Chundury A; Wu AJ; Hathout L; Hallemeier CL; Jabbour SK
Cancer Med; 2021 Jun; 10(11):3575-3583. PubMed ID: 33960690
[TBL] [Abstract][Full Text] [Related]
13. Diagnosis-shift between low-grade serous ovarian cancer and serous borderline ovarian tumor: A population-based study.
Matsuo K; Machida H; Grubbs BH; Matsuzaki S; Klar M; Roman LD; Sood AK; Gershenson DM
Gynecol Oncol; 2020 Apr; 157(1):21-28. PubMed ID: 31954535
[TBL] [Abstract][Full Text] [Related]
14. The impact of age at the time of radiotherapy for localized prostate cancer on the development of second primary malignancies.
Krasnow RE; Rodríguez D; Nagle RT; Mossanen M; Kibel AS; Chang SL
Urol Oncol; 2018 Nov; 36(11):500.e11-500.e19. PubMed ID: 30249519
[TBL] [Abstract][Full Text] [Related]
15. Second Primary Malignancy in Bladder Carcinoma - A Population-based Study.
Khanal A; Budhathoki N; Singh VP; Shah BK
Anticancer Res; 2017 Apr; 37(4):2033-2036. PubMed ID: 28373478
[TBL] [Abstract][Full Text] [Related]
16. Second Primary Malignancies in Mantle Cell Lymphoma: A US Population-based Study.
Shah BK; Khanal A
Anticancer Res; 2015 Jun; 35(6):3437-40. PubMed ID: 26026107
[TBL] [Abstract][Full Text] [Related]
17. Second primary malignancy among malignant solid tumor survivors aged 85 years and older.
Zhang Z; Liu F; Qu Y; Qiu L; Zhang L; Yang Q
Sci Rep; 2021 Oct; 11(1):19748. PubMed ID: 34611235
[TBL] [Abstract][Full Text] [Related]
18. Secondary Primary Malignancy Risk in Patients With Ovarian Cancer in Taiwan: A Nationwide Population-Based Study.
Hung YP; Liu CJ; Hu YW; Chen MH; Li CP; Yeh CM; Chiou TJ; Chen TJ; Yang MH; Chao Y
Medicine (Baltimore); 2015 Sep; 94(38):e1626. PubMed ID: 26402833
[TBL] [Abstract][Full Text] [Related]
19. Second nonbreast malignancies after conservative surgery and radiation therapy for early-stage breast cancer.
Galper S; Gelman R; Recht A; Silver B; Kohli A; Wong JS; Van Buren T; Baldini EH; Harris JR
Int J Radiat Oncol Biol Phys; 2002 Feb; 52(2):406-14. PubMed ID: 11872286
[TBL] [Abstract][Full Text] [Related]
20. Epidemiological analysis of second primary malignant neoplasms in cancer survivors aged 85 years and older: a SEER data analysis (1975-2016).
Zhao X; Zhang L; Bai L; Zhao Y; Yang Q
Sci Rep; 2022 Jul; 12(1):11688. PubMed ID: 35803964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
